Article
Licensed
Unlicensed
Requires Authentication
Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System
-
Stefan Holdenrieder
Published/Copyright:
May 1, 2008
Abstract
Background: Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer.
Methods: The analytical and clinical performance of the Access OV Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA125 on the Elecsys System (Roche Diagnostics).
Results: Total imprecision (%CV) of the OV Monitor ranged between 3.1% and 8.8%, and inter-laboratory reproducibility between 4.7% and 5.0%. Linearity upon dilution showed a mean recovery of 100% (SD+8.1%). Endogenous interferents had no influence on OV Monitor levels (mean recoveries: hemoglobin 107%, bilirubin 103%, triglycerides 103%). There was no high-dose hook effect up to 27,193 kU/L. Clinical performance investigated in sera from 1811 individuals showed a good correlation between the Access OV Monitor and Elecsys CA125 (R=0.982, slope=0.921, intercept=+1.951). OV Monitor serum levels were low in healthy individuals (n=267, median=9.7 kU/L, 95th percentile=30.8 kU/L), higher in individuals with various benign diseases (n=549, medians=10.9–16.4 kU/L, 95th percentiles=44.2–355 kU/L) and even higher in individuals suffering from various cancers (n=995, medians=12.4–445 kU/L; 95th percentiles=53.4–4664 kU/L). Optimal diagnostic accuracy for cancer detection against the relevant benign control group by the OV Monitor was found for ovarian cancer [area under the curve (AUC) 0.898]. Results for the reference CA125 assay were comparable (AUC 0.899).
Conclusions: The Access OV Monitor provides very good methodological characteristics and demonstrates an excellent analytical and clinical correlation with Elecsys CA125. The best diagnostic accuracy for the OV Monitor was found in ovarian cancer. Our results also suggest a clinical value of the OV Monitor in other cancers.
Clin Chem Lab Med 2008;46:588–99.
Received: 2007-7-3
Accepted: 2007-10-4
Published Online: 2008-05-01
Published in Print: 2008-05-01
©2008 by Walter de Gruyter Berlin New York
You are currently not able to access this content.
You are currently not able to access this content.
Articles in the same Issue
- Editorial
- Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics?
- Review
- The diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases
- Validation and Outcome Studies
- Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System
- Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® GI Monitor assay on the UniCel® DxI 800 Immunoassay System
- Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System
- Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards
- Multicentre evaluation of a new point-of-care test for the determination of CK-MB in whole blood
- Down's syndrome screening: population statistic dependency of screening performance
- General Clinical Chemistry and Laboratory Medicine
- Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease
- Role for mitochondrial uncoupling protein-2 (UCP2) in hyperhomocysteinemia and venous thrombosis risk?
- Plasma procalcitonin measured by time-resolved amplified cryptate emission (TRACE) in liver transplant patients. A prognosis marker of early infectious and non-infectious postoperative complications
- Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease
- Association of thyroid stimulating hormone and coronary lipid risk factors with lipid peroxidation in hypothyroidism
- The effect of the mode of delivery on the maternal-neonatal carnitine blood levels and antioxidant status
- Time to reconsider the clinical value of immunoglobulin G4 to foods?
- Reference Values
- Determination of reference intervals for 26 commonly measured biochemical analytes with consideration of long-term within-individual variation
- Beverage-specific effects of ethanol consumption on its biological markers
- Limits of preservation of samples for urine strip tests and particle counting
- Reference ranges and diagnostic thresholds of laboratory markers of cardiac damage and dysfunction in a population of apparently healthy black Africans
- Letters to the Editor
- External quality assessment schemes for real-time PCR: a statistical procedure to corrective actions
- Application of two different microarray-based copy-number detection methodologies – array-comparative genomic hybridization and array-multiplex amplifiable probe hybridization – with identical amplifiable target sequences
- Criticism to the article: “Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method.” Authors: J.O. Jeppsson et al. Clin Chem Lab Med 2007;45(4):558–562
- Standardization of carbohydrate-deficient transferrin: reply to the letter by Tagliaro and Bortolotti
- Comment on: Bellini C, Serra G, Risso D, Mazzella M, Bonioli E. Reliability assessment of glucose measurement by HemoCue analyser in a neonatal intensive care unit. Clin Chem Lab Med 2007;45(11):1549–54
- Reliability assessment of glucose measurement by HemoCue analyzer in a neonatal intensive care unit: reply to Dr. Joakim Hagvik
Articles in the same Issue
- Editorial
- Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics?
- Review
- The diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases
- Validation and Outcome Studies
- Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System
- Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® GI Monitor assay on the UniCel® DxI 800 Immunoassay System
- Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System
- Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards
- Multicentre evaluation of a new point-of-care test for the determination of CK-MB in whole blood
- Down's syndrome screening: population statistic dependency of screening performance
- General Clinical Chemistry and Laboratory Medicine
- Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease
- Role for mitochondrial uncoupling protein-2 (UCP2) in hyperhomocysteinemia and venous thrombosis risk?
- Plasma procalcitonin measured by time-resolved amplified cryptate emission (TRACE) in liver transplant patients. A prognosis marker of early infectious and non-infectious postoperative complications
- Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease
- Association of thyroid stimulating hormone and coronary lipid risk factors with lipid peroxidation in hypothyroidism
- The effect of the mode of delivery on the maternal-neonatal carnitine blood levels and antioxidant status
- Time to reconsider the clinical value of immunoglobulin G4 to foods?
- Reference Values
- Determination of reference intervals for 26 commonly measured biochemical analytes with consideration of long-term within-individual variation
- Beverage-specific effects of ethanol consumption on its biological markers
- Limits of preservation of samples for urine strip tests and particle counting
- Reference ranges and diagnostic thresholds of laboratory markers of cardiac damage and dysfunction in a population of apparently healthy black Africans
- Letters to the Editor
- External quality assessment schemes for real-time PCR: a statistical procedure to corrective actions
- Application of two different microarray-based copy-number detection methodologies – array-comparative genomic hybridization and array-multiplex amplifiable probe hybridization – with identical amplifiable target sequences
- Criticism to the article: “Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method.” Authors: J.O. Jeppsson et al. Clin Chem Lab Med 2007;45(4):558–562
- Standardization of carbohydrate-deficient transferrin: reply to the letter by Tagliaro and Bortolotti
- Comment on: Bellini C, Serra G, Risso D, Mazzella M, Bonioli E. Reliability assessment of glucose measurement by HemoCue analyser in a neonatal intensive care unit. Clin Chem Lab Med 2007;45(11):1549–54
- Reliability assessment of glucose measurement by HemoCue analyzer in a neonatal intensive care unit: reply to Dr. Joakim Hagvik
